XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2
Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Error Corrections and Prior Period Adjustments Restatement [Line Items]                
Other asset impairments, restructuring and other items [1] $ 280 $ 108 $ 954 $ 218        
Operating income (loss) [1] (5) (654) (223) (667)        
Income (loss) before income taxes [1] (246) (923) (713) (1,195)        
Income taxes (benefit) 630 (16) 578 (35)        
Net income (loss) (874) (906) (1,294) (1,159)        
Net income (loss) attributable to Teva $ (846) $ (872) $ (985) $ (1,091)        
Earnings (loss) per share attributable to ordinary shareholders:                
Basic $ (0.75) $ (0.78) $ (0.87) $ (0.98)        
Diluted $ (0.75) $ (0.78) $ (0.87) $ (0.98)        
Deferred income taxes $ 2,000 $ 1,583 $ 2,000 $ 1,583   $ 1,812    
Total assets 41,338 43,100 41,338 43,100   43,479    
Other taxes and long-term liabilities 4,356 4,094 4,356 4,094   4,019    
Total long-term liabilities 21,737 23,664 21,737 23,664   23,106    
Total liabilities 34,774 35,508 34,774 35,508   35,353    
Teva shareholders' equity:                
Accumulated deficit (14,519) (14,066) (14,519) (14,066)   (13,534)    
Total equity 6,563 7,592 6,563 7,592 $ 7,543 8,126 $ 8,504 $ 8,598
Total liabilities and equity $ 41,338 43,100 $ 41,338 43,100   $ 43,479    
As previously reported [Member]                
Error Corrections and Prior Period Adjustments Restatement [Line Items]                
Other asset impairments, restructuring and other items   100   195        
Operating income (loss)   (646)   (644)        
Income (loss) before income taxes   (914)   (1,172)        
Income taxes (benefit)   (16)   (35)        
Net income (loss)   (898)   (1,136)        
Net income (loss) attributable to Teva   $ (863)   $ (1,068)        
Earnings (loss) per share attributable to ordinary shareholders:                
Basic   $ (0.77)   $ (0.96)        
Diluted   $ (0.77)   $ (0.96)        
Deferred income taxes   $ 1,578   $ 1,578        
Total assets   43,095   43,095        
Other taxes and long-term liabilities   3,973   3,973        
Total long-term liabilities   23,543   23,543        
Total liabilities   35,387   35,387        
Teva shareholders' equity:                
Accumulated deficit   (13,950)   (13,950)        
Total equity   7,708   7,708        
Total liabilities and equity   43,095   43,095        
Adjustment [Member]                
Error Corrections and Prior Period Adjustments Restatement [Line Items]                
Other asset impairments, restructuring and other items   8   23        
Operating income (loss)   (8)   (23)        
Income (loss) before income taxes   (8)   (23)        
Income taxes (benefit)       0        
Net income (loss)   (8)   (23)        
Net income (loss) attributable to Teva   $ (8)   $ (23)        
Earnings (loss) per share attributable to ordinary shareholders:                
Basic   $ (0.01)   $ (0.02)        
Diluted   $ (0.01)   $ (0.02)        
Deferred income taxes   $ 5   $ 5        
Total assets   5   5        
Other taxes and long-term liabilities   121   121        
Total long-term liabilities   121   121        
Total liabilities   121   121        
Teva shareholders' equity:                
Accumulated deficit   (116)   (116)        
Total equity   (116)   (116)        
Total liabilities and equity   $ 5   $ 5        
[1] The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements.